Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Cancer Chemotherapy and Pharmacology|April 9, 2016
Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapyNeta Goldschmidt, Geffen Kleinstern, Marina Orevi, et al.
American Journal of Hematology|November 3, 2016
Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapyAdir Shaulov, Chezi Ganzel, Noam Benyamini, et al.
European Journal of Haematology|October 5, 2012
Insect-bite-like reaction in patients with chronic lymphocytic leukemia: a study from the Israeli Chronic Lymphocytic Leukemia Study GroupOsnat Bairey, Neta Goldschmidt, Rosa Ruchlemer, et al.
European Journal of Haematology|February 18, 2018
Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosisMarjorie Pick, Vladimir Vainstein, Neta Goldschmidt, et al.
Cancer|June 24, 2010
Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerantMaya Koren-Michowitz, Philipp le Coutre, Justus Duyster, et al.
Hematological Oncology|July 5, 2023
A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma-Outcomes indicative for improved survival overtimeOsnat Bairey, Eyal Lebel, Chen Buxbaum, et al.
Anticancer Research|February 11, 2014
Hodgkin's variant of Richter transformation in chronic lymphocytic leukemia; a retrospective study from the Israeli CLL study groupTamar Tadmor, Lev Shvidel, Neta Goldschmidt, et al.
American Journal of Hematology|August 12, 2014
Richter's transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study GroupTamar Tadmor, Lev Shvidel, Osnat Bairey, et al.
Leukemia & Lymphoma|February 15, 2014
Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemiaJacob Vine, Sara Bar Cohen, Rosa Ruchlemer, et al.
Annals of Hematology|August 23, 2016
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocolMoshe Mittelman, Kalman Filanovsky, Yishai Ofran, et al.
Pageof 8